CymaBay is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Their lead asset, Seladelpar, is a first-in-class oral, selective PPARδ agonist shown to regulate critical metabolic and liver disease pathways in indications with high unmet medical need. Preclinical and clinical data support its ability to regulate genes involved in bile acids synthesis, inflammation, fibrosis and lipid metabolism, storage and transport. CymaBay is currently dosing patients in its pivotal Phase 3 RESPONSE clinical trial for patients with Primary Biliary Cholangitis. The company is listed on Nasdaq with ticker: CBAY.